injectable therapy) and comorbidities/co-medication ( The triple therapy of metformin, a DPP-4 inhibitor and a SGLT-2 inhibitor has a very low treatment related hypoglycaemia risk, leads to a further, almost additive reduction of glycaemic parameters, a body weight loss in the same range as with a mono- or dual therapy with a SGLT-2 inhibitor and also to the expected SGLT-2 inhibitor induced reduction of blood pressure
[DOI] [PMC free article] [PubMed] [Google Scholar] 439.Zhou P, et al
Hence, purging can only result from products with active ingredients such as Retinol, Benzoyl Peroxide, Hydroxy acids, L ascorbic acid, etc
[ClinicalTrials.gov] ClinicalTrials.gov
I have received a few direct messaged from people who were getting menopause care through MIDI and who experienced an unwanted upsell for GLP-1s